For this reason, intravitreal injections of anti-VEGF drugs are currently the gold standard of care for macular edema in RVO due to their demonstrated efficacy in addressing the underlying pathophysiology of this disease [69]. This evidence concerns the gene VEGFA and macular retinal edema.